. Author manuscript; available in PMC: 2020 Oct 1.

Published in final edited form as: Nat Cancer. 2020 Mar 23;1(4):382–393. doi: 10.1038/s43018-020-0047-1

Table 2.

Dose limiting toxicity

Dose-limiting toxicity (Grade)	Arm A Daily (n=7)		Arm B Daily (n=7)	Arm C 7d on, 7d off (n=12)		Arm D 5d on, 2d off (n=15)			All Arms^§ (n=41)
Dose-limiting toxicity (Grade)	250mg n=3	300mg n=4	300mg n=7	250mg n=6	300mg n=6	250mg n=3	300mg n=6	350mg n=6	All Arms^§ (n=41)
Maculopapular rash	1 (G3)	2 (G3)	4 (G3)	0	1 (G3)	0	1 (G3)	1 (G3)	10 (G3)
Hyperglycemia	0	0	1 (G3)	0	0	0	0	0	1 (G3)
Hypotension	0	0	0	0	1 (G3)	0	0	0	1 (G3)
Abdominal pain	0	1 (G3)^*	0	0	0	0	0	0	1 (G3)

G3 abdominal pain constituted DLT as it warranted hospitalization.

^§

The Arm D expansion cohort (b=10) was not included in the DLT assessment.